Skip to main content

Table 3 Subsequent treatment after first-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance

From: Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Group Total (cases) Continuation of TKI [cases (%)] AZD9291 [cases (%)] Chemo ± RT [cases (%)] TKI plus chemo/RT [cases (%)] BSC [cases (%)]
CF
 T790M+ 72 23 (31.9) 28 (38.9) 10 (13.9) 4 (5.6) 7 (9.7)
 T790M− 103 41 (39.8) 23 (22.3) 21 (20.4) 9 (8.7) 9 (8.7)
 Total 175 64 (36.6) 51 (29.1) 31 (17.7) 13 (7.4) 16 (9.1)
BF
 T790M+ 6 1 (16.7) 1 (16.7) 0 (0) 0 (0) 4 (66.7)
 T790M− 21 9 (42.9) 3 (14.3) 2 (9.5) 2 (9.5) 5 (23.8)
 Total 27 10 (37.0) 4 (14.8) 2 (7.4) 2 (7.4) 9 (33.3)
OF
 T790M+ 53 10 (18.9) 22 (41.5) 11 (20.8) 4 (7.5) 6 (11.3)
 T790M− 23 7 (30.4) 8 (34.8) 3 (13) 1 (4.3) 4 (17.4)
 Total 76 17 (22.4) 30 (39.5) 14 (18.4) 5 (6.6) 10 (13.2)
  1. CF, progressive disease limited to the chest in lung/pleural tissues and lymph nodes, with no evidence of progression beyond the chest; BF, progressive disease in a previously existing site or a new site of metastatic disease in the brain, with no evidence of extracranial progression; OF, progressive disease in other distant sites or multiple sites including the chest and intracranial region
  2. TKI tyrosine kinase inhibitor, Chemo chemotherapy, RT radiotherapy, BSC best supportive care